Peer-Reviewed Publications

[35] Roopa Rajan, Kanwaljeet Garg, Arti Saini, Divya MR, Miryam Carecchio, Binukumar BK, Manmohan Singh, Achal K Srivastava. GPi-DBS for KMT2B-associated dystonia: systematic review and meta-analysis. Movement Disorders ClinicalPractice.Firstpublished:16November2021https://doi.org/10.1002/mdc3.13374

[34] Paras Sehgal, Samatha Mathew, Ambily Sivadas, Arjun Ray, Jyoti Tanwar, Sushma Vishwakarma, Gyan Ranjan, K V Shamsudheen, Rahul C Bhoyar, Abhishek Pateria, Elvin Leonard, Mukesh Lalwani, Archana Vats, Rajeev R Pappuru, Mudit Tyagi, Saumya Jakati, Shantanu Sengupta, Binukumar BK, Subhabrata Chakrabarti, Inderjeet Kaur, Rajender K Motiani, Vinod Scaria, Sridhar Sivasubbu. LncRNA VEAL2 regulates PRKCB2 to modulate endothelial permeability in diabetic retinopathy. EMBO J (2021)e107134. doi.org/10.15252/embj.2020107134

[33] Sahana S, Sivadas A, Mangla M, Jain A, Bhoyar RC, Pandhare K, Mishra A, Sharma D, Imran M, Senthivel V, Divakar MK, Rophina M, Jolly B, Batra A, Sharma S, Siwach S, Jadhao AG, Palande NV, Jha GN, Ashrafi N, Mishra PK, Vidhya AK, Jain S, Dash D, Kumar NS, Vanlallawma A, Sarma RJ, Chhakchhuak L, Kalyanaraman S, Mahadevan R, Kandasamy S, Devi P, Rajagopal RE, Ramya JE, Devi PN, Bajaj A, Gupta V, Mathew S, Goswami S, Prakash S, Joshi K, Kumla M, Sreedevi S, Gajjar D, Soraisham R, Yadav R, Devi YS, Gupta A, Mukerji M, Ramalingam S, Binukumar BK, Sivasubbu S, Scaria V. Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes. Pharmacogenomics. 2021 Jul;22(10):603-618.

[32] Sangita Paul, Debarpita Saha and Binukumar BK^*. Mitochondrial dysfunction and mitophagy closely cooperate in neurological deficits associated with Alzheimer’s disease and type 2 diabetes. Mol Neurobiol. 2021 Apr 1. doi: 10.1007/s12035-021-02365-2. (*,corresponding author)

[31] Roopa Rajan, Kanwaljeet Garg, Arti Saini, Mukesh Kumar, Binukumar BK, Vinod Scaria, Rajeev Aggarwal, Achal K Srtivastava, Manmohan Singh. Pallidal Deep Brain Stimulation for KMT2B related dystonia in an Indian patient. Annals of Indian Academy of Neurology (Provisionally accepted) DOI: 10.4103/aian.AIAN_1316_20

[30] Jain A, Bhoyar RC,Pandhare K, Mishra A, Sharma D,Imran M, Senthivel V,Divakar1 MK, Rophina M, Jolly B, Batra A,Sharma S, Siwach S,Jadhao AG, Palande NV, Jha GN, Ashrafi N, Mishra PK, Vidhya AK, Jain S, Dash D, Senthil Kumar N, Vanlallawma A, Sarma RJ, Chhakchhuak L, Kalyanaraman S,Mahadevan R, Kandasamy S, Pabitha BM, Rajagopal RE, Ramya E, Nirmala Devi P, Bajaj A, Gupta V, Mathew S,Goswami SG, Mangla M, Prakash S, Joshi K, Meyakumla, Sreedevi S, Gajjar D, Ronibala Soraisham, Yadav R, Silla Devi Y, Gupta A, Mukerji M, Ramalingam S, Binukumar BK, Scaria V,Sivasubbu S. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Research (2020) doi: 10.1093/nar/gkaa923

[29] Aditi Mhaske, Dileep KV, Mukesh Kumar, Mukta Poojary, Kavita Pandhare, Kam Y. J. Zhang, Vinod Scaria*, and Binukumar BK*. ATP7A Clinical Genetics Resource - a comprehensive clinically annotated database and resource for genetic variants in ATP7A gene. Computational and Structural Biotechnology Journal (CSBJ) Volume 18, 2020, Pages 2347-2356 (*, corresponding author)

[28] Mukesh Kumar, Utkarsh Gaharwar, Sangita Paul, Mukta Poojary, Kavita Pandhare, Vinod Scaria* and Binukumar BK* WilsonGen a comprehensive clinically annotated genomic variant resource for Wilson’s Disease.Sci Rep. 2020 Jun 3;10(1):9037. (*, corresponding author)

[27] ICROWD Consortium, Binukumar BK*. The Indian Collaborative Research on Wilson’s Disease-an effort to understand the genetic epidemiology of Wilson's Disease in India. Translational Genomics. 2020, Vol. 1 No. 1 (2020): Issue 1.Perspective (*, corresponding author)

[26] Binukumar BK*, Skuntz S, Prochazkova M, Kesavapany S, Amin ND, Varsha Shukla, Grant P, Kulkarni AB, Pant HC*. Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model.Hum Mol Genet. 2019 Jun 12. pii: ddz118. (*, corresponding author)

[25] Berry C, Lal M, Binukumar BK*.Crosstalk Between the Unfolded Protein Response, MicroRNAs, and Insulin Signaling Pathways: In Search of Biomarkers for the Diagnosis and Treatment of Type 2 Diabetes.Front Endocrinol (Lausanne). 2018 May 2;9:210. eCollection 2018. Review. (*, corresponding author)

[24] Hall BE, Prochazkova M, Sapio MR, Minetos P, Kurochkina N, Binukumar BK, Amin ND, Terse A, Pant HC, Chung MK, Iadarola MJ, Kulkarni AB.Phosphorylation of the Transient Receptor Potential Ankyrin 1 by Cyclin-dependent Kinase 5 affects Chemo-nociception. Sci Rep. 2018 Jan 19;8(1):1177.

[23] Prochazkova M, Hall B, Hu M, Okine T, Reukauf J, Binukumar BK, Amin ND, Roque E, Pant HC, Kulkarni A . Peripheral and orofacial pain sensation is unaffected by the loss of p39. Mol Pain. 2017 Jan-Dec;13:1744806917737205.

[22] Shukla V, Seo J, Binukumar BK, Amin ND, Grant P, Kuntz S, Kesavapany S, Steiner J, Tsai LH, Pant HC. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice. J Alzheimers Dis. 2017;56(1):335-349.

[21] Amin ND, Zheng Y, BK B, Shukla V, Skuntz S, Grant P, Steiner J, Bhaskar M, Pant HC The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35. Mol Biol Cell. 2016 Nov 1;27(21):3221-3232.

[20] Binukumar BK, Pelech SL, Sutter C, Shukla V, Amin ND, Grant P, Bhaskar M, Skuntz S, Steiner J, Pant HC Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases. J Alzheimers Dis. 2016 Sep 6;54(2):525-33.

[19] Binukumar BK, Pant HC . TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease. Neural Regen Res. 2016 May;11(5):698-701. Review

[18] Binukumar BK, Shukla V, Amin ND, Bhaskar M, Skuntz S, Steiner J, Winkler D, Pelech SL, Pant HC. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein. J Alzheimers Dis. 2015;48(4):1009-17.

[17] Binukumar BK, Shukla V, Amin ND, Grant P, Bhaskar M, Skuntz S, Steiner J, Pant HC. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease. Mol Biol Cell. 2015 Dec 1;26(24):4478-91. (A Highlights from MBoC Selection)

[16] Binukumar BK, Zheng YL, Shukla V, Amin ND, Grant P, Pant HC. TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity. J Alzheimers Dis. 2014;39(4):899-909.

[15] Binukumar BK, Shukla V, Amin ND, Reddy P, Skuntz S, Grant P, Pant HC. Topographic regulation of neuronal intermediate filaments by phosphorylation, role of peptidyl-prolyl isomerase 1: significance in neurodegeneration. Histochem Cell Biol. 2013 Jul;140(1):23-32. Review

[14] Kandimalla RJ, Wani WY, Binukumar BK, Gill KD. siRNA against presenilin 1 (PS1) down regulates amyloid β42 production in IMR-32 cells. J Biomed Sci. 2012 Jan 3;19:2.

[13] Binukumar BK, Gupta N, Sunkaria A, Kandimalla R, Wani WY, Bal A, Gill KD. Protective efficacy of coenzyme Q10 against DDVP-induced cognitive impairments and neurodegeneration in rats. Neurotox Res. 2012 May;21(4):345-57.

[12] Gupta N, Binu KB, Singh S, Maturu NV, Sharma YP, Bhansali A, Gill KD. Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics.Gene. 2012 Apr 25;498(1):13-9.

[11] Binukumar BK, Bal A, Gill KD.Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system. Neuromolecular Med. 2011 Dec;13(4):251-65.

[10] Binukumar BK, Gupta N, Bal A, Gill KD.Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic coenzyme Q10 pretreatment. Toxicol Appl Pharmacol. 2011 Oct 1;256(1):73-82.

[9]Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A, Gill KD.Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gene. 2011 Nov 1;487(1):88-95.

[8] Anand R, Binukumar BK, Gill KD.Aluminum phosphide poisoning: an unsolved riddle. J Appl Toxicol. 2011 Aug;31(6):499-505.

[7] Dwivedi N, Mehta A, Yadav A, Binukumar BK, Gill KD, Flora SJ. MiADMSA reverses impaired mitochondrial energy metabolism and neuronal apoptotic cell death after arsenic exposure in rats. Toxicol Appl Pharmacol. 2011 Nov 1;256(3):241-8.

[6] Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, Bhardwaj N, Jain K, Gill KD. Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease. Curr Alzheimer Res. 2011 Mar;8(2):187-96.

[5] Kandimalla RJ, S P, BK B, Wani WY, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.Neurosci Lett. 2011 Jan 7;487(2):134-8.

[4] Binukumar BK, Bal A, Kandimalla RJ, Gill KD. Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes. Mol Brain. 2010 Nov 13;3:35.

[3] Binukumar BK, Gill KD. Cellular and molecular mechanisms of dichlorvos neurotoxicity: cholinergic, nonchlolinergic, cell signaling, gene expression and therapeutic aspects. Indian J Exp Biol. 2010 Jul;48(7):697-709. Review.

[2] Binukumar BK, Bal A, Kandimalla R, Sunkaria A, Gill KD. Mitochondrial energy metabolism impairment and liver dysfunction following chronic exposure to dichlorvos. Toxicology. 2010 Apr 11;270(2-3):77-84.

[1] Sharma A, Kaur P, Kumar B, Prabhakar S, Gill KD. Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. Parkinsonism Relat Disord. 2008;14(1):52-7.